abstract |
The invention discloses an IgG1 type antibody, which has a modified Fc region, and the region lacks the function of regulating effectors, a pharmaceutical preparation method comprising the antibody, and an IgG1 type anti-human TNFR1 antibody used as TNF antagonists are used without forming agonistic TNFR1 signaling complexes, as an alternative to the use of anti-TNF therapeutics. |